GPT and metabolic dysfunction-associated steatohepatitis: According to a review article on clinical trials of MASH published in July 2023 [50], cotadutide studied in 74 patients demonstrated a moderate impact on the hepatic fat fraction, ALT, and AST after 19 weeks in the cotadutide cohort compared to the placebo group.